Head to Head Survey: Cancer Genetics (CGIX) and Celcuity (CELC)

Celcuity (NASDAQ:CELC) and Cancer Genetics (NASDAQ:CGIX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

Valuation & Earnings

This table compares Celcuity and Cancer Genetics’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Celcuity N/A N/A -$6.25 million N/A N/A
Cancer Genetics $29.12 million 0.43 -$20.88 million ($0.79) -0.57

Celcuity has higher earnings, but lower revenue than Cancer Genetics.

Insider & Institutional Ownership

14.4% of Celcuity shares are held by institutional investors. Comparatively, 13.6% of Cancer Genetics shares are held by institutional investors. 43.5% of Celcuity shares are held by insiders. Comparatively, 21.3% of Cancer Genetics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Celcuity and Cancer Genetics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Celcuity 0 0 1 0 3.00
Cancer Genetics 0 2 1 0 2.33

Celcuity currently has a consensus price target of $35.00, suggesting a potential upside of 49.19%. Cancer Genetics has a consensus price target of $4.50, suggesting a potential upside of 900.00%. Given Cancer Genetics’ higher possible upside, analysts plainly believe Cancer Genetics is more favorable than Celcuity.

Volatility & Risk

Celcuity has a beta of 0.21, suggesting that its share price is 79% less volatile than the S&P 500. Comparatively, Cancer Genetics has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500.

Profitability

This table compares Celcuity and Cancer Genetics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Celcuity N/A -24.34% -23.67%
Cancer Genetics -54.98% -81.99% -40.24%

Summary

Celcuity beats Cancer Genetics on 7 of the 10 factors compared between the two stocks.

Celcuity Company Profile

Celcuity Inc., a cellular analysis company, discovers cancer sub-types and commercializes diagnostic tests to enhance the response rates of cancer patients treated with targeted therapies in the United States. The company is developing CELx tests to diagnose two new sub-types of HER2-negative breast cancer. It is also developing CELx tests to diagnose 14 new potential cancer sub-types in breast, lung, colon, ovarian, kidney, bladder, and hematological cancers. The company was founded in 2012 and is headquartered in Minneapolis, Minnesota.

Cancer Genetics Company Profile

Cancer Genetics, Inc. develops, commercializes, and provides molecular and biomarker-based tests and services in the United States, Europe, and Asia. Its tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology and immuno-oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. The company's biopharma services offer companies with customized solutions for patient stratification and treatment selection through a suite of molecular- and biomarker-based testing services, customized assay development, and trial design consultation. Its clinical services provide information on diagnosis, prognosis, and predicting treatment outcomes of cancers to guide patient management. The company's discovery services offer the tools and testing methods for companies and researchers to identify and develop new compounds and molecular-based biomarkers for diagnostics and treatment of disease. It serves hospitals, cancer centers, clinics, academic institutions, and government-sponsored research institutions, as well as pharmaceutical and biotech companies performing clinical trials. The company collaborates with oncology centers and community-based hospitals to develop its proprietary diagnostic tests; and has collaboration with Cellaria to develop precision medicine tools and platform technologies to support the development of new cancer therapeutics. Cancer Genetics, Inc. was founded in 1999 and is based in Rutherford, New Jersey.

Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply